Developer docs
API playgroundTry for free, no card

Search company profiles

Ventus Medical

Full company profile

uuid000b5v6

Namestring
Ventus Medical
Legal namestring
Ventus Medical LTD
Websiteurl
ventusmedical.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ventus Medical LTD is a privately held UK medical device and pharmaceutical development company headquartered in Liverpool, founded in 2015 by David Lawson and Mark Dignum, both previously responsible for the world's first medically approved electronic cigarette (e-VOKE, MHRA-licensed in 2013) at Nerudia. The company has spent nine years developing ENHALE, a CE-marked electronic nicotine inhaler that delivers nicotine via proprietary low-temperature vaporisation through replaceable single-dose cartridges, avoiding the thermal degradants and metals associated with conventional vaping products.

ENHALE is positioned as the first innovation in licensed nicotine replacement therapy in over a decade and is intended to serve adult smokers and adult vapers seeking to reduce or quit nicotine consumption in the UK and, subsequently, Europe. The product has secured ISO 13485, ISO 9001, and ISO 14001 certifications from the British Standards Institution, and the company submitted a UK Marketing Authorisation Application to the MHRA in May 2024.

The business model centres on hardware sales of the ENHALE device and recurring cartridge replacement revenue, distributed through UK pharmacies and healthcare providers as a non-prescription product once MHRA approval is granted. The company is backed by Advent Life Sciences as its primary venture investor, with General Partner Kaasim Mahmood serving as Chairman. Ventus Medical is currently pre-revenue, with commercial launch contingent on regulatory approval.

Short descriptiontext

Ventus Medical LTD is a UK-based medical device developer building ENHALE, a CE-marked, low-temperature vaporisation nicotine inhaler for adult smokers and vapers seeking cessation, pending MHRA marketing authorisation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLiverpool, United Kingdom
HQ citystring
Liverpool
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nicotine replacement therapy, smoking cessation devices, medical device inhalers, tobacco harm reduction, electronic NRT products
Industry3 codes
1Smoking Cessation & Nicotine Replacement Therapy (NRT)
CodeHLAIADAHPrimaryYes
2Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
CodeHLAHAGAEPrimaryNo
3Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges)
CodeCRADAMAIPrimaryNo
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1ENHALE Product Sales
TypeHardware Sales
Description

Revenue from sale of ENHALE nicotine inhaler devices and replacement cartridges. Product will be available without prescription upon regulatory approval in the UK and subsequently Europe.

ventusmedical.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ventus Medical develops and markets ENHALE, a CE-marked medical device and electronic nicotine replacement therapy (NRT) inhaler that delivers nicotine through proprietary low-temperature vaporisation technology with replaceable single-dose nicotine cartridges. The product is designed for adult smokers and vapers seeking to reduce or quit nicotine consumption, providing safer nicotine delivery without thermal degradants or metals in the aerosol. The product is currently undergoing UK MHRA marketing authorisation review and will subsequently be submitted in Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • ENHALE demonstrated to alleviate nicotine withdrawal symptoms quicker than leading NRT products whilst using less nicotine
Product overview1 text field

Ventus Medical is a medical device and pharmaceutical development company offering a single unified product: ENHALE, a novel electronic nicotine replacement therapy inhaler. ENHALE is the company's principal development product and first innovation in licensed medicine in over a decade. It features proprietary low-temperature vaporisation technology and single-dose nicotine cartridges within a certified medical device, providing safer nicotine delivery compared to traditional vaping or smoking.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ventus Medical

ventusmedical.com

Ventus Medical LTD is a UK-based medical device developer building ENHALE, a CE-marked, low-temperature vaporisation nicotine inhaler for adult smokers and vapers seeking cessation, pending MHRA marketing authorisation.

What Ventus Medical does

Ventus Medical LTD is a privately held UK medical device and pharmaceutical development company headquartered in Liverpool, founded in 2015 by David Lawson and Mark Dignum, both previously responsible for the world's first medically approved electronic cigarette (e-VOKE, MHRA-licensed in 2013) at Nerudia. The company has spent nine years developing ENHALE, a CE-marked electronic nicotine inhaler that delivers nicotine via proprietary low-temperature vaporisation through replaceable single-dose cartridges, avoiding the thermal degradants and metals associated with conventional vaping products.

ENHALE is positioned as the first innovation in licensed nicotine replacement therapy in over a decade and is intended to serve adult smokers and adult vapers seeking to reduce or quit nicotine consumption in the UK and, subsequently, Europe. The product has secured ISO 13485, ISO 9001, and ISO 14001 certifications from the British Standards Institution, and the company submitted a UK Marketing Authorisation Application to the MHRA in May 2024.

The business model centres on hardware sales of the ENHALE device and recurring cartridge replacement revenue, distributed through UK pharmacies and healthcare providers as a non-prescription product once MHRA approval is granted. The company is backed by Advent Life Sciences as its primary venture investor, with General Partner Kaasim Mahmood serving as Chairman. Ventus Medical is currently pre-revenue, with commercial launch contingent on regulatory approval.

Ventus Medical firmographics

Firmographics
Name
Ventus Medical
Legal name
Ventus Medical LTD
Website
https://ventusmedical.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Ventus Medical LTD is a UK-based medical device developer building ENHALE, a CE-marked, low-temperature vaporisation nicotine inhaler for adult smokers and vapers seeking cessation, pending MHRA marketing authorisation.
Ownership category
akta.pro rank

Ventus Medical industry classification

Industry
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro primary industry
Smoking Cessation & Nicotine Replacement Therapy (NRT) (HLAIADAH)
akta.pro secondary industries
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges) (CRADAMAI)

Keywords

  • Nicotine replacement therapy
  • Smoking cessation devices
  • Medical device inhalers
  • Tobacco harm reduction
  • Electronic NRT products

Where Ventus Medical is headquartered

Location

Headquarters

HQ city
Liverpool
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Ventus Medical business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing

Revenue model

  1. ENHALE Product Sales: Revenue from sale of ENHALE nicotine inhaler devices and replacement cartridges. Product will be available without prescription upon regulatory approval in the UK and subsequently Europe.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Ventus Medical product offering

Product offering

Core offering

Ventus Medical develops and markets ENHALE, a CE-marked medical device and electronic nicotine replacement therapy (NRT) inhaler that delivers nicotine through proprietary low-temperature vaporisation technology with replaceable single-dose nicotine cartridges. The product is designed for adult smokers and vapers seeking to reduce or quit nicotine consumption, providing safer nicotine delivery without thermal degradants or metals in the aerosol. The product is currently undergoing UK MHRA marketing authorisation review and will subsequently be submitted in Europe.

Product overview

Ventus Medical is a medical device and pharmaceutical development company offering a single unified product: ENHALE, a novel electronic nicotine replacement therapy inhaler. ENHALE is the company's principal development product and first innovation in licensed medicine in over a decade. It features proprietary low-temperature vaporisation technology and single-dose nicotine cartridges within a certified medical device, providing safer nicotine delivery compared to traditional vaping or smoking.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • ENHALE demonstrated to alleviate nicotine withdrawal symptoms quicker than leading NRT products whilst using less nicotine

Companies that use Ventus Medical

Customer profile

Segments1 record

Ventus Medical technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ventus Medical partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Ventus Medical competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

Ventus Medical social profiles

Digital presence

Ventus Medical compliance and trust

Trust signal

Compliance5 records

Ventus Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ventus Medical leadership team

Management profile

Number of profiles

Ventus Medical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ventus Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventus Medical

What does Ventus Medical do?

Ventus Medical develops and markets ENHALE, a CE-marked medical device and electronic nicotine replacement therapy (NRT) inhaler that delivers nicotine through proprietary low-temperature vaporisation technology with replaceable single-dose nicotine cartridges. The product is designed for adult smokers and vapers seeking to reduce or quit nicotine consumption, providing safer nicotine delivery without thermal degradants or metals in the aerosol. The product is currently undergoing UK MHRA marketing authorisation review and will subsequently be submitted in Europe.

Is Ventus Medical a public or private company?

Ventus Medical is a private company. It is currently operating.

When was Ventus Medical founded?

Ventus Medical was founded in 2015. It employs 1 to 10 people.

Where is Ventus Medical based?

Ventus Medical is headquartered in Liverpool, United Kingdom, in the Europe region.

How does Ventus Medical make money?

One revenue line is on record: ENHALE Product Sales.

Does Ventus Medical have an API?

No public API is recorded for Ventus Medical.

What industry is Ventus Medical in?

Its primary akta.pro industry code is HLAIADAH, Smoking Cessation & Nicotine Replacement Therapy (NRT), with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 339113 and its SIC code is 5047.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Sleep ReviewEPAP Gets a New LookVentus Medical, now part of Foundation Consumer Healthcare, has established EPAP therapy as a mainstream treatment for sleep apnea and snoring through its Provent and Theravent devices. New entrants including Hüpnos, Oventus Medical, and AirAvant Medical are introducing updated reusable EPAP technologies featuring integrated sensors, oral appliance compatibility, and nasal dilation to improve patient comfort and efficacy.SleepdtA Novel Non-Prescription Nasal EPAP Device (Theravent) to Treat SnoringVentus Medical introduced Theravent, a novel non-prescription nasal EPAP device designed to treat primary snoring by creating resistance during exhalation to maintain upper airway patency. Clinical studies demonstrated that the device significantly reduced snoring duration and volume compared to control groups, with responders achieving an average reduction of 76% in snoring time.PR NewswireProvent® Sleep Apnea Therapy Now Available in IndiaVentus Medical announced the launch of its Provent® Sleep Apnea Therapy in India, partnering with Orbees Business Solutions Pvt. Ltd. as the strategic market developer for the region. The company cites a high prevalence of obstructive sleep apnea in India, noting that roughly 20% of urban males suffer from the condition, to justify the expansion into this emerging market.GlobeNewswireVentus Medical Completes $40 Million Financing and Announces New President and CEOVentus Medical closed a $40 million Series D financing and named Peter Wyles president and CEO. Proceeds will expand commercialization of PROVENT, a sleep apnea therapy. Wyles joins from Bayer HealthCare.GlobeNewswireNew Data Support Effectiveness of Ventus Medical's PROVENT(r) Therapy in Treating Obstructive Sleep ApneaVentus Medical presented three poster presentations at SLEEP 2009 confirming PROVENT Therapy's clinical utility for obstructive sleep apnea. The data showed a 49% reduction in AHI and suggested positive end-expiratory pressure as the mechanism of action. The therapy is available in limited U.S. locations with physician support.